BAZ2-ICR is an epigenetic chemical probe and it also is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 2-3 weeks | $ 86 | |
4 mg | 2-3 weeks | $ 163 | |
8 mg | 2-3 weeks | $ 246 | |
20 mg | 2-3 weeks | $ 468 | |
40 mg | 2-3 weeks | $ 702 |
Description | BAZ2-ICR is an epigenetic chemical probe and it also is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains. |
Targets&IC50 | BAZ2A:(kd)109 nM, BAZ2A:130 nM, BAZ2A:170 nM(kd), BAZ2B:180 nM |
In vitro | To investigate whether BAZ2-ICR (Compound 13) can displace BAZ2 bromodomains from chromatin in living cells. A fluorescence recovery after photobleaching (FRAP) assay utilizing GFP-tagged BAZ2A full length protein transfected into human osteosarcoma cells (U2OS) are tested. 1 μM BAZ2-ICR reduces the recovery time of the wild-type (wt) construct to a level similar to the dominant negative mutant, confirming that BAZ2-ICR inhibits BAZ2A in cells. |
In vivo | BAZ2-ICR (5 mg/kg) shows 70% bioavailability and moderate clearance (~50% of mouse liver blood flow) and volume of distribution. BAZ2-ICR (Compound 13) shows very high solubility (25 mM in D2O), a measured log D of 1.05. High stability in mouse microsomes, and permeation in the CaCo-2 model and thus a suitable profile for oral and intravenous gavage. |
CAS No. | 1665195-94-7 |
Chemical Formula | C20H19N7 |
Molecular Weight | 357.421 |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom